2025年血栓症和止血生物標記全球市場報告

預計血栓症和止血生物標記市場規模將在未來幾年強勁成長。預計到 2029 年將成長到 68.7 億美元，年複合成長率（CAGR）為 7.4%。推動這一成長的因素包括中風和缺血性事件的急劇增加、人們對靜脈血栓栓塞症的認知不斷提高、血友病等出血性疾病的患病率不斷上升、外科手術的增加以及醫療保健預算的擴大。預測期內預計會出現的顯著趨勢包括生物標記檢測技術的進步、D-二聚體和纖維蛋白原超靈敏檢測法的開發、照護現場診斷工具的興起、人工智慧在生物標記解釋和預測中的應用以及臨床測試自動化程度的提高。

精準標靶治療需求的不斷成長預計將在未來幾年推動血栓症和止血生物標記市場的成長。這些治療方法是先進的治療方法，專注於患者疾病的分子和遺傳特徵，旨在提高療效並最大限度地減少副作用。不斷成長的需求源於對疾病基因和分子突變的深入了解，這使得個人化治療成為可能，從而獲得更好的療效並降低風險。這一趨勢推動了能夠識別特定生物標記的更精準診斷工具的開發，從而支持血栓症和止血生物標記市場的發展，從而實現更有效、更個人化的凝血障礙治療。例如，總部位於澳洲的委外研發機構(CRO) Novotech 在 2024 年 3 月報告稱，在 2023 年底前將獲得 FDA核准的 217 種抗癌藥物中，43% 將被歸類為精準腫瘤藥物，其中 78 種將包含可透過 DNA 或次世代定序儀(NGS) 檢測的生物標記。因此，對這些標靶治療的不斷成長的需求預計將推動市場擴張。

血栓症和止血生物標記市場中的公司正在不斷開發先進的診斷解決方案，例如自動化 VWF 活性檢測法，以提高出血性疾病檢測的準確性和可靠性。自動化 VWF 活性檢測法一種高通量測試，它使用免疫比濁法和化學冷光等技術來評估血管性血友病因子 (VWF) 與血小板糖蛋白 Ib 的結合效率，VWF 是參與止血的關鍵糖蛋白，而血小板糖蛋白 Ib 對於血管性血友病的診斷和監測至關重要。例如，2022 年 10 月，德國醫療技術公司西門子醫療推出了 INNOVANCE VWF Ac檢測法，這是一項全自動測試，旨在提高 VWF 活性測量的準確性。此檢測法利用 VWF GPIbM 技術，可直接評估血小板結合活性，並且比傳統方法具有更高的靈敏度和準確性。 VWF被廣泛認為是與出血和血栓症形成相關的生物標記物，這項新的檢測法將有助於識別先前無法檢測的VWF變異體，從而提高血管性血友病的診斷能力。此外，此檢測法符合美國血液學會(ASH)、國際血栓與止血學會(ISTH)和美國國家血友病基金會(NHF)的最新臨床指南，凸顯了現代診斷方法的重要性。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球血栓症與止血生物標記：PESTEL 分析（政治、社會、技術、環境、法律、促進因素、限制因素）
• 最終用途產業分析
• 全球血栓症和止血生物標記市場：成長率分析
• 全球血栓症和止血生物標記市場表現：規模與成長，2019-2024
• 全球血栓症和止血生物標記市場預測：規模與成長，2024-2029，2034
• 全球血栓症和止血生物標記：總目標市場（TAM）

第6章市場區隔

• 全球血栓症和止血生物標記市場（按產品、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 試劑和耗材
• 分析器
• 全球血栓症和止血生物標記市場（按測試類型、性能和預測）2019-2024 年、2024-2029 年、2034 年
• D-二聚體
• 抗凝血酶III
• 胞漿素原
• 可溶性纖維蛋白
• 第八因子
• 凝血酶後（PT）
• 活化部份凝血活酵素時間(APTT) 測試
• 其他
• 全球血栓症和止血生物標記市場的應用、表現和預測，2019-2024 年、2024-2029 年、2034 年
• 心血管疾病
• 神經系統疾病
• 腫瘤學
• 妊娠相關疾病
• 整形外科手術
• 全球血栓症和止血生物標記市場（按最終用戶、績效和預測）2019-2024 年、2024-2029 年、2034 年
• 醫院
• 診斷實驗室
• 製藥公司
• 學術機構
• 家庭醫療保健
• 全球血栓症和止血生物標記市場：試劑和耗材細分（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 凝血試劑
• 控制和校準材料
• 免疫檢測套件
• 全球血栓症和止血生物標記市場：分析儀器細分（按類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
• 全自動凝血分析儀
• 半自動凝血分析儀
• 照護現場凝血分析儀

第7章 區域和國家分析

• 全球血栓症及止血生物標記市場（按地區、績效及預測）2019-2024、2024-2029、2034
• 全球血栓症和止血生物標記市場（按國家/地區、績效和預測）2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 血栓症和止血生物標記市場：競爭格局
• 血栓症和止血生物標記市場：公司簡介
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • Becton, Dickinson and Company（BD）Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• Mayo Clinic Laboratories
• bioMerieux SA
• Beckman Coulter Inc.
• QuidelOrtho Corporation
• Bio-Rad Laboratories Inc.
• Cincinnati Children's Hospital Medical Center
• ARUP Laboratories
• HORIBA Ltd.
• Werfen SA
• Pathkind Diagnostics Pvt. Ltd.
• Diagnostica Stago
• Agilus Diagnostics
• Helena Laboratories Corporations
• Cleveland Clinic Laboratories
• Diazyme Laboratories Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年血栓症和止血生物標記市場：提供新機會的國家
• 2029 年血栓症和止血生物標記市場：細分市場帶來新機會
• 2029年血栓症和止血生物標記市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Thrombosis and hemostasis biomarkers are biological indicators that offer valuable insights into the mechanisms of blood clot formation and the regulation of bleeding. These biomarkers play a vital role in monitoring the equilibrium between clot development and its breakdown, serving as essential tools in evaluating vascular health and diagnosing coagulation-related disorders.

The primary products in the thrombosis and hemostasis biomarkers market include reagents and consumables as well as analyzers. Reagents and consumables encompass crucial chemical agents and disposable lab supplies-such as assay kits, buffers, calibrators, and control solutions-used for detecting, measuring, and analyzing biomarkers associated with clotting and bleeding conditions. These products are utilized in a variety of diagnostic tests, including D-dimer, anti-thrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin (PT), activated partial thromboplastin time (APTT), and others. Their applications span across cardiovascular diseases, neurological disorders, cancer, pregnancy-related complications, and orthopedic surgeries. Key end users of these biomarkers include hospitals, diagnostic laboratories, pharmaceutical firms, academic research centers, and home healthcare providers.

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $4.80 billion in 2024 to $5.17 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. Growth during the historical period was driven by factors such as a rise in cardiovascular disease prevalence, an aging population, an increase in cancer-related thrombosis, a surge in obesity and sedentary behavior, as well as the growing burden of diabetes and metabolic disorders.

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $6.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Factors fueling this projected growth include a surge in cases of stroke and ischemic events, heightened awareness of venous thromboembolism, an increased incidence of bleeding disorders like hemophilia, a growing number of surgical interventions, and expanding healthcare budgets. Notable trends anticipated during the forecast period include advancements in biomarker detection technologies, the development of ultra-sensitive assays for D-dimer and fibrinogen, the rise of point-of-care diagnostic tools, the integration of artificial intelligence for biomarker interpretation and forecasting, and increased automation in clinical laboratory testing.

The increasing demand for precise and targeted therapies is anticipated to drive the growth of the thrombosis and hemostasis biomarkers market in the coming years. These therapies are advanced treatment approaches that focus on the molecular and genetic characteristics of a patient's disease, aiming to improve efficacy while minimizing side effects. The rise in demand stems from a deeper understanding of genetic and molecular variations in diseases, which allows for more individualized treatment, thereby enhancing therapeutic outcomes and reducing risks. This trend supports the thrombosis and hemostasis biomarkers market by facilitating the development of more accurate diagnostic tools that can identify specific biomarkers, leading to more effective and tailored treatments for clotting disorders. For example, in March 2024, Novotech, an Australia-based contract research organization (CRO), reported that 43% of the 217 FDA-approved oncology therapies by the end of 2023 are categorized as precision oncology treatments, with 78 of them incorporating DNA or Next Generation Sequencing (NGS)-detectable biomarkers. As a result, the growing demand for these targeted therapies is expected to fuel market expansion.

Companies in the thrombosis and hemostasis biomarkers market are increasingly developing advanced diagnostic solutions such as automated VWF activity assays to improve the accuracy and reliability of bleeding disorder testing. An automated VWF activity assay is a high-throughput laboratory test that employs techniques like immunoturbidimetry or chemiluminescence to evaluate the binding efficiency of von Willebrand factor (VWF)-a key glycoprotein involved in hemostasis-to platelet glycoprotein Ib. This is essential for diagnosing and monitoring von Willebrand disease. For instance, in October 2022, Siemens Healthineers, a Germany-based medical technology company, introduced the INNOVANCE VWF Ac assay, a fully automated test designed to enhance the precision of VWF activity measurement. Utilizing VWF:GPIbM technology, this assay directly evaluates platelet binding activity and offers improved sensitivity and accuracy over earlier methods. As VWF is a widely recognized biomarker associated with both bleeding and thrombosis, the new assay helps in identifying previously undetectable VWF variants, thus enhancing diagnostic capabilities for von Willebrand disease. Moreover, it aligns with the latest clinical guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Hemostasis (ISTH), and the National Hemophilia Foundation (NHF), underscoring its importance in modern diagnostic practices.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This strategic acquisition aims to strengthen Procuritas' presence in the growing thrombosis and hemostasis diagnostics market. Precision BioLogic, based in Canada, offers FDA-cleared reagents and plasma-based products, along with strong research and development capabilities. Affinity Biologicals, also based in Canada, specializes in manufacturing products used in thrombosis and hemostasis research and diagnostics, including custom assay services. The deal is expected to leverage the strengths of both companies to capitalize on global healthcare trends and expand Procuritas' diagnostic portfolio.

Major players in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Mayo Clinic Laboratories, bioMerieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cincinnati Children's Hospital Medical Center, ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH.

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombosis and hemostasis biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombosis And Hemostasis Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombosis and hemostasis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombosis and hemostasis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombosis and hemostasis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Reagents And Consumables; Analyzers
• 2) By Test Type: D-Dimer; Anti-Thrombin III; Plasminogen; Soluble Fibrin; Factor VIII; Post-Thrombin (PT); Activated Partial Thromboplastin Time (APTT) Test; Other Test Types
• 3) By Application: Cardiovascular Disorders; Neurological Disorders; Oncology; Pregnancy-Related Disorders; Orthopedic Procedures
• 4) By End User: Hospitals; Diagnostics Laboratories; Pharmaceutical Companies; Academic Institutions; Home Healthcare Settings
• Subsegments:
• 1) By Reagents And Consumables: Coagulation Reagents; Control And Calibration Materials; Immunoassay Kits
• 2) By Analyzers: Fully Automated Coagulation Analyzers; Semi-Automated Coagulation Analyzers; Point-Of-Care Coagulation Devices
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Becton, Dickinson and Company (BD)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thrombosis And Hemostasis Biomarkers Market Characteristics

3. Thrombosis And Hemostasis Biomarkers Market Trends And Strategies

4. Thrombosis And Hemostasis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Thrombosis And Hemostasis Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Thrombosis And Hemostasis Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Thrombosis And Hemostasis Biomarkers Market Growth Rate Analysis
• 5.4. Global Thrombosis And Hemostasis Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Thrombosis And Hemostasis Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Thrombosis And Hemostasis Biomarkers Total Addressable Market (TAM)

6. Thrombosis And Hemostasis Biomarkers Market Segmentation

• 6.1. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reagents And Consumables
• Analyzers
• 6.2. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• D-Dimer
• Anti-Thrombin III
• Plasminogen
• Soluble Fibrin
• Factor VIII
• Post-Thrombin (PT)
• Activated Partial Thromboplastin Time (APTT) Test
• Other Test Types
• 6.3. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Disorders
• Neurological Disorders
• Oncology
• Pregnancy-Related Disorders
• Orthopedic Procedures
• 6.4. Global Thrombosis And Hemostasis Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostics Laboratories
• Pharmaceutical Companies
• Academic Institutions
• Home Healthcare Settings
• 6.5. Global Thrombosis And Hemostasis Biomarkers Market, Sub-Segmentation Of Reagents And Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Coagulation Reagents
• Control And Calibration Materials
• Immunoassay Kits
• 6.6. Global Thrombosis And Hemostasis Biomarkers Market, Sub-Segmentation Of Analyzers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fully Automated Coagulation Analyzers
• Semi-Automated Coagulation Analyzers
• Point-Of-Care Coagulation Devices

7. Thrombosis And Hemostasis Biomarkers Market Regional And Country Analysis

• 7.1. Global Thrombosis And Hemostasis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Thrombosis And Hemostasis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market

• 8.1. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thrombosis And Hemostasis Biomarkers Market

• 9.1. China Thrombosis And Hemostasis Biomarkers Market Overview
• 9.2. China Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thrombosis And Hemostasis Biomarkers Market

• 10.1. India Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thrombosis And Hemostasis Biomarkers Market

• 11.1. Japan Thrombosis And Hemostasis Biomarkers Market Overview
• 11.2. Japan Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thrombosis And Hemostasis Biomarkers Market

• 12.1. Australia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thrombosis And Hemostasis Biomarkers Market

• 13.1. Indonesia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thrombosis And Hemostasis Biomarkers Market

• 14.1. South Korea Thrombosis And Hemostasis Biomarkers Market Overview
• 14.2. South Korea Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thrombosis And Hemostasis Biomarkers Market

• 15.1. Western Europe Thrombosis And Hemostasis Biomarkers Market Overview
• 15.2. Western Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thrombosis And Hemostasis Biomarkers Market

• 16.1. UK Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thrombosis And Hemostasis Biomarkers Market

• 17.1. Germany Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thrombosis And Hemostasis Biomarkers Market

• 18.1. France Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thrombosis And Hemostasis Biomarkers Market

• 19.1. Italy Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thrombosis And Hemostasis Biomarkers Market

• 20.1. Spain Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thrombosis And Hemostasis Biomarkers Market

• 21.1. Eastern Europe Thrombosis And Hemostasis Biomarkers Market Overview
• 21.2. Eastern Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thrombosis And Hemostasis Biomarkers Market

• 22.1. Russia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thrombosis And Hemostasis Biomarkers Market

• 23.1. North America Thrombosis And Hemostasis Biomarkers Market Overview
• 23.2. North America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thrombosis And Hemostasis Biomarkers Market

• 24.1. USA Thrombosis And Hemostasis Biomarkers Market Overview
• 24.2. USA Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thrombosis And Hemostasis Biomarkers Market

• 25.1. Canada Thrombosis And Hemostasis Biomarkers Market Overview
• 25.2. Canada Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thrombosis And Hemostasis Biomarkers Market

• 26.1. South America Thrombosis And Hemostasis Biomarkers Market Overview
• 26.2. South America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thrombosis And Hemostasis Biomarkers Market

• 27.1. Brazil Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thrombosis And Hemostasis Biomarkers Market

• 28.1. Middle East Thrombosis And Hemostasis Biomarkers Market Overview
• 28.2. Middle East Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thrombosis And Hemostasis Biomarkers Market

• 29.1. Africa Thrombosis And Hemostasis Biomarkers Market Overview
• 29.2. Africa Thrombosis And Hemostasis Biomarkers Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Thrombosis And Hemostasis Biomarkers Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Thrombosis And Hemostasis Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thrombosis And Hemostasis Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Thrombosis And Hemostasis Biomarkers Market Competitive Landscape
• 30.2. Thrombosis And Hemostasis Biomarkers Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Becton, Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis

31. Thrombosis And Hemostasis Biomarkers Market Other Major And Innovative Companies

• 31.1. Mayo Clinic Laboratories
• 31.2. bioMerieux S.A.
• 31.3. Beckman Coulter Inc.
• 31.4. QuidelOrtho Corporation
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. Cincinnati Children's Hospital Medical Center
• 31.7. ARUP Laboratories
• 31.8. HORIBA Ltd.
• 31.9. Werfen S.A.
• 31.10. Pathkind Diagnostics Pvt. Ltd.
• 31.11. Diagnostica Stago
• 31.12. Agilus Diagnostics
• 31.13. Helena Laboratories Corporations
• 31.14. Cleveland Clinic Laboratories
• 31.15. Diazyme Laboratories Inc.

32. Global Thrombosis And Hemostasis Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thrombosis And Hemostasis Biomarkers Market

34. Recent Developments In The Thrombosis And Hemostasis Biomarkers Market

35. Thrombosis And Hemostasis Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Thrombosis And Hemostasis Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Thrombosis And Hemostasis Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Thrombosis And Hemostasis Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer